Literature DB >> 21637950

Treatment of multiple sclerosis: current concepts and future perspectives.

Dorothea Buck1, Bernhard Hemmer.   

Abstract

Currently, several disease-modifying therapies for the treatment of multiple sclerosis are established and more are likely to be introduced. These treatment options differ with respect to their application profile, mechanism of action, efficacy, safety, and tolerance. Here, we review current concepts of MS therapies, report recent results of clinical trials, and discuss emerging treatment options.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21637950     DOI： 10.1007/s00415-011-6101-2

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   6.682


  109 in total

1.  Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.

Authors:  A T Reder; G C Ebers; A Traboulsee; D Li; D Langdon; D S Goodin; T Bogumil; K Beckmann; A Konieczny
Journal:  Neurology       Date:  2010-06-08       Impact factor: 9.910

2.  Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials.

Authors:  I L Tan; G J Lycklama à Nijeholt; C H Polman; H J Adèr; F Barkhof
Journal:  Mult Scler       Date:  2000-04       Impact factor: 6.312

Review 3.  Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.

Authors:  Thomas A Waldmann
Journal:  J Clin Immunol       Date:  2007-01-11       Impact factor: 8.317

Review 4.  Mitoxantrone for multiple sclerosis.

Authors:  F Martinelli Boneschi; M Rovaris; R Capra; G Comi
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

5.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Authors:  Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Bhupendra O Khatri; Xavier Montalban; Jean Pelletier; Ruggero Capra; Paolo Gallo; Guillermo Izquierdo; Klaus Tiel-Wilck; Ana de Vera; James Jin; Tracy Stites; Stacy Wu; Shreeram Aradhye; Ludwig Kappos
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

6.  Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications.

Authors:  Ruth Arnon; Rina Aharoni
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-15       Impact factor: 11.205

7.  Daclizumab in treatment of multiple sclerosis patients.

Authors:  E N Ali; B C Healy; L A Stazzone; B A Brown; H L Weiner; S J Khoury
Journal:  Mult Scler       Date:  2009-01-09       Impact factor: 6.312

8.  Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

Authors:  Mark C Genovese; Jeffrey L Kaine; Mitchell B Lowenstein; José Del Giudice; Andrew Baldassare; Joy Schechtman; Edward Fudman; Michael Kohen; Sheila Gujrathi; Robert G Trapp; Nadera J Sweiss; Greg Spaniolo; Wolfgang Dummer
Journal:  Arthritis Rheum       Date:  2008-09

9.  IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).

Authors:  Joanne L Jones; Chia-Ling Phuah; Amanda L Cox; Sara A Thompson; Maria Ban; Jacqueline Shawcross; Amie Walton; Stephen J Sawcer; Alastair Compston; Alasdair J Coles
Journal:  J Clin Invest       Date:  2009-06-22       Impact factor: 14.808

10.  Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.

Authors:  F Sellebjerg; M Krakauer; D Hesse; L P Ryder; I Alsing; P E H Jensen; N Koch-Henriksen; A Svejgaard; P Soelberg Sørensen
Journal:  Eur J Neurol       Date:  2009-06-22       Impact factor: 6.089
View more
  25 in total

1.  Astrocyte-derived endothelin-1 inhibits remyelination through notch activation.

Authors:  Timothy R Hammond; Ana Gadea; Jeff Dupree; Christophe Kerninon; Brahim Nait-Oumesmar; Adan Aguirre; Vittorio Gallo
Journal:  Neuron       Date:  2014-02-05       Impact factor: 17.173

Review 2.  [Vitamin D and multiple sclerosis : the role for risk of disease and treatment].

Authors:  A Döring; F Paul; J Dörr
Journal:  Nervenarzt       Date:  2013-02       Impact factor: 1.214

3.  Erythropoietin attenuates neurological and histological consequences of toxic demyelination in mice.

Authors:  Nora Hagemeyer; Susann Boretius; Christoph Ott; Axel Von Streitberg; Henrike Welpinghus; Swetlana Sperling; Jens Frahm; Mikael Simons; Pietro Ghezzi; Hannelore Ehrenreich
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

4.  Activation of necroptosis in multiple sclerosis.

Authors:  Dimitry Ofengeim; Yasushi Ito; Ayaz Najafov; Yaoyang Zhang; Bing Shan; Judy Park DeWitt; Juanying Ye; Xumin Zhang; Ansi Chang; Helin Vakifahmetoglu-Norberg; Jiefei Geng; Benedicte Py; Wen Zhou; Palak Amin; Jonilson Berlink Lima; Chunting Qi; Qiang Yu; Bruce Trapp; Junying Yuan
Journal:  Cell Rep       Date:  2015-03-24       Impact factor: 9.423

5.  A2A adenosine receptor signaling in lymphocytes and the central nervous system regulates inflammation during experimental autoimmune encephalomyelitis.

Authors:  Jeffrey H Mills; Do-Geun Kim; Antje Krenz; Jiang-Fan Chen; Margaret S Bynoe
Journal:  J Immunol       Date:  2012-04-23       Impact factor: 5.422

6.  Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE.

Authors:  Xianzhen Hu; Stephen Tomlinson; Scott R Barnum
Journal:  Neurosci Lett       Date:  2012-10-16       Impact factor: 3.046

7.  Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE.

Authors:  Xianzhen Hu; V Michael Holers; Joshua M Thurman; Trent R Schoeb; Theresa N Ramos; Scott R Barnum
Journal:  Mol Immunol       Date:  2013-01-20       Impact factor: 4.407

8.  Regulation of Th1 cells and experimental autoimmune encephalomyelitis by glycogen synthase kinase-3.

Authors:  Eléonore Beurel; Oksana Kaidanovich-Beilin; Wen-I Yeh; Ling Song; Valle Palomo; Suzanne M Michalek; James R Woodgett; Laurie E Harrington; Hagit Eldar-Finkelman; Ana Martinez; Richard S Jope
Journal:  J Immunol       Date:  2013-04-19       Impact factor: 5.422

Review 9.  Thyroid Hormone Potentially Benefits Multiple Sclerosis via Facilitating Remyelination.

Authors:  Mao Zhang; Ziyi Ma; Haochen Qin; Zhongxiang Yao
Journal:  Mol Neurobiol       Date:  2015-08-05       Impact factor: 5.590

10.  Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis.

Authors:  Anna Ridderstad Wollberg; Anders Ericsson-Dahlstrand; Anders Juréus; Petra Ekerot; Sylvia Simon; Maria Nilsson; Stig-Johan Wiklund; Anna-Lena Berg; Mats Ferm; Dan Sunnemark; Rolf Johansson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-25       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.